First-in-human evidence of multidrug resistance reversal in solid tumors: a cohort analysis of carbon nanoparticles‑Fe(II) complex trials - PubMed
5 hours ago
- #nanomedicine
- #ferroptosis
- #multidrug resistance
- Phase I trial (NCT06048367) of carbon nanoparticles-Fe(II) complex (CNSI-Fe) involving 19 patients evaluated safety and multidrug resistance reversal in solid tumors.
- CNSI-Fe showed acceptable safety, induced central necrosis on imaging, and minimal tumor shrinkage per RECIST v1.1.
- Four patients (21.1%) achieved long-term survival (28.9-36.2 months) and restored sensitivity to previously resistant chemotherapies or targeted agents (e.g., paclitaxel, bevacizumab).
- Results suggest CNSI-Fe may weaken multidrug resistance and resensitize tumors, supporting further biomarker-integrated Phase II trials combined with other therapies.